Case Studies

Challenge: A drug discovery company preparing for a forthcoming funding round wanted to update a valuation of the business based on a series of contract research projects and the proprietary value in...

Challenge: A biotech company with a novel oral drug delivery technology platform was looking to out-license its lead asset, a reformulated generic therapeutic in a new, non-opioid pain, indication,...

Challenge: Alacrita was engaged by a strategic investor to conduct initial due diligence on a new EGFR therapeutic strategy in oncology.

Challenge: Alacrita was engaged by a strategic investor to conduct initial due diligence on a novel observation and potential product opportunity in Alzheimer’s disease.

Challenge A private biotech company developing gene therapy products for several orphan diseases was in the process of initiating CMC development for their pipeline products. In order to move...

Challenge A leading private US academic institution, recognizing the need to further develop early discoveries from the university in order to facilitate industry partnerships and clinical...

Challenge A private investment firm was seeking an independent reality-check on a potential investment in a pharmaceutical company that had recently in-licensed a generic therapeutic asset. The firm...

Challenge: A biotech company developing a platform technology to improve the safety of CAR T-cell therapies asked Alacrita to conduct a comprehensive competitive landscape to better understand the...

Challenge A small molecule pharmaceutical incubator is using a novel and proprietary drug discovery and translational platform to develop first-in-class, small molecule therapeutics for the treatment...

Alacrita provides both in- and out-licensing support to a number of pharmaceutical and biotech organizations and companies. Below you'll find a series of case studies related to this service.

Challenge Our client specialized in the development of proprietary monoclonal antibodies directed towards novel targets for the treatment of immune-mediated and fibrotic disorders, including orphan...

Challenge A stem cell research company had developed a target product profile (TPP) for a novel therapy for glioblastoma (GBM). The company asked Alacrita to conduct a comprehensive review of the GBM...